• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

    16.05 +0.51 (+3.28%)
    Streaming Delayed Price Updated: 2:26 PM EST, Feb 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Adaptive Biotechnologies Corporation - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
    Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
    Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
    30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
    clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
    Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
    From Adaptive Biotechnologies
    Via GlobeNewswire
    News headline image
    Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
    From Adaptive Biotechnologies
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.